-
New FMF Recommendations Tackle Drug Resistance and Fertility
18 Apr 2025 12:18 GMT
… equitable access to treatment and individualizing interventions based … six randomized controlled trials with IL-1 blockers … but other options include anakinra and rilonacept.
“We … stakeholders, including pharmaceutical companies that produce drugs listed in …
-
U.S. FDA grants interchangeable designation to YUFLYMA® (adalimumab-aaty), Celltrion’s biosimilar to Humira® (adalimumab)
15 Apr 2025 01:31 GMT
… FDA approved for the treatment of patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis … global pharmaceutical portfolio … drugs to push the boundaries of scientific innovation and deliver quality medicines … in biotechnology, …
-
Perspectives on Talquetamab and its Utility in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
02 Apr 2025 16:43 GMT
… by the Food and Drug Administration (FDA) for use in … Trials
Searle et al reported on the phase 1b MonumenTAL-2 trial … patients discontinued treatment due to xerostomia. Common medications employed to … alternative agents such as anakinra may be considered.47
…
-
Anakinra Market Analysis: Key Trends, Share, Growth Drivers, And Forecast 2025-2034
24 Mar 2025 15:11 GMT
… administered treatment options, collaborations between biotech … anakinra remains an effective treatment for inflammatory conditions like rheumatoid arthritis … medical conditions, come after evaluating the drug… fully FDA-approved for COVID-19 treatment, it …
-
The Word Salad of Branded Drugs: How a Prescription Name is Chosen
24 Mar 2025 12:24 GMT
… treatment.
This is the lifespan of a drug … drug names of the past, including Anakinra, for rheumatoid arthritis … other drug names. The FDA guidance recommends pharmaceutical companies … drug names.
Names can be different across a border. Prozac, an antidepressant …
-
FDA Warning ‘Bombshell’ Caps Top JIA Developments for 2024
20 Mar 2025 12:06 GMT
For juvenile idiopathic arthritis (JIA), 2024 … were deemed drug tolerant during biologic treatment and retrospectively … glucocorticoids, and high-dose anakinra, along with other agents … Medical Center, included the 14 participants of the phase 2 EMERALD trial …
-
October - December 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
05 Mar 2025 21:57 GMT
…
FDA is evaluating the need for regulatory action.
Ilaris (canakinumab)
Kineret (anakinra)
Drug … reaction with eosinophilia and systemic symptoms
FDA is evaluating …
-
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution
25 Feb 2025 12:30 GMT
… and Drug Administration (FDA) for the treatment of … your doctor right away. Treatment with … Kineret® (anakinra), or medicines that block tumor … 922,915
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
SELECTED CONSOLIDATED BALANCE …
-
Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy
25 Feb 2025 12:29 GMT
… (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA … Food and Drug Administration (FDA) for the treatment of recurrent … call your doctor right away. Treatment with ARCALYST … as Kineret® (anakinra), or medicines that block tumor …
-
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
24 Feb 2025 06:00 GMT
… stability compared with reference medicine
Basel, February 24 … and Drug Administration (FDA) for the treatment of … conditions — including rheumatoid arthritis, plaque psoriasis, Crohn … DRUG INTERACTIONS: Abatacept: Increased risk of serious infection. Anakinra …
About
© 1995-2025